or Try an Advanced Search...

    Technical Analysis for ENLV - Enlivex Therapeutics Ltd.

    Grade Last Price % Change Price Change
    F 1.44 -0.69% -0.01
    ENLV closed down 0.69 percent on Friday, April 26, 2024, on 29 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical ENLV trend table...
    Date Alert Name Type % Chg
    Boomer Sell Setup Bearish Swing Setup 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    1,2,3 Retracement Bearish Bearish Swing Setup -0.69%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.69%
    Narrow Range Bar Range Contraction -0.69%
    Inside Day Range Contraction -0.69%
    Wide Bands Range Expansion -0.69%
    Oversold Stochastic Weakness -0.69%
    Older End-of-Day Signals for ENLV ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 14 hours ago
    Possible Inside Day about 14 hours ago
    Up 2% about 18 hours ago
    Up 1% about 18 hours ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ENLV Chart by TradingView
    Basic chart:

    Profile

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Immunology Solid Tumors Immune System Immunotherapy Cancer Treatment Tumor Virotherapy Coronavirus Cytokine Inflammatory Conditions

    Is ENLV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
    Apr 16 Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
    Apr 15 Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
    Apr 11 Nasdaq Jumps 250 Points; Crude Oil Down 1%
    Apr 11 Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
    Apr 11 Enlivex stock plunges 50% on mixed results from sepsis study
    Apr 11 Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
    Mar 22 Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Feb 26 Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
    Feb 21 Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
    See more ENLV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.59
    52 Week Low 1.15
    Average Volume 197,983
    200-Day Moving Average 2.42
    50-Day Moving Average 3.14
    20-Day Moving Average 2.48
    10-Day Moving Average 1.39
    Average True Range 0.32
    RSI (14) 30.56
    ADX 37.29
    +DI 15.22
    -DI 38.52
    Chandelier Exit (Long, 3 ATRs) 3.62
    Chandelier Exit (Short, 3 ATRs) 2.12
    Upper Bollinger Bands 5.03
    Lower Bollinger Band -0.07
    Percent B (%b) 0.3
    BandWidth 205.84
    MACD Line -0.62
    MACD Signal Line -0.54
    MACD Histogram -0.0812
    Fundamentals Value
    Market Cap 26.78 Million
    Num Shares 18.6 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -0.98
    Price-to-Sales 0.00
    Price-to-Book 1.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.53
    Resistance 3 (R3) 1.54 1.52 1.52
    Resistance 2 (R2) 1.52 1.50 1.52 1.51
    Resistance 1 (R1) 1.48 1.48 1.47 1.47 1.50
    Pivot Point 1.46 1.46 1.46 1.46 1.46
    Support 1 (S1) 1.42 1.44 1.41 1.41 1.38
    Support 2 (S2) 1.40 1.42 1.40 1.37
    Support 3 (S3) 1.36 1.40 1.37
    Support 4 (S4) 1.35